News
Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ...
Capital Market on MSN5d
Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic GelAccording to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax (R) SM) had estimated annual sales of $29 million in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback